ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 33 of 41 for:    Recruiting, Not yet recruiting, Available Studies | "Unrelated Donors"

Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02593123
Recruitment Status : Recruiting
First Posted : October 30, 2015
Last Update Posted : January 31, 2018
Sponsor:
Collaborator:
Massey Cancer Center
Information provided by (Responsible Party):
Virginia Commonwealth University

Brief Summary:
Determine the relapse-free, donor lymphocyte infusion (DLI)-free survival in patients receiving the investigational regimen.This is a randomized phase II clinical trial, comparing two different dosing schedules of mycophyenolate mofetil for graft versus host disease (GVHD) prevention following allogeneic stem cell transplantation. Risk for relapse, GVHD and non-relapse mortality will be assessed. Adaptive randomization between two study arms will be performed based on T cell counts at day 60.

Condition or disease Intervention/treatment Phase
Hodgkin's Lymphoma Lymphoid Leukemia Lymphoma Leukemia Myeloma Acute Lymphocytic Leukemia Non Hodgkin Lymphoma Chronic Lymphocytic Leukemia Multiple Myeloma Chronic Myelogenous Leukemia Myelodysplastic Syndromes Recurrent Acute Myeloid Leukemia, Adult Recurrent Hodgkin Lymphoma Recurrent Non-Hodgkin Lymphoma Recurrent Plasma Cell Myeloma Recurrent Chronic Lymphocytic Leukemia Recurrent Chronic Myelogenous Leukemia Acute Myelogenous Leukemia Drug: mycophenolate mofetil Biological: Sargramostim Biological: Filgrastim Phase 2

Detailed Description:
In this study, the investigators will utilize a regimen combining low dose total body irradiation and rabbit ATG to facilitate stem cell transplantation (SCT) with HLA matched related and unrelated donors. Based on the hypothesis that early treatment interventions have significant late effects in allogeneic SCT, a simple intervention, varying the duration of intense immunosuppression following SCT, will be investigated in this study. This may allow more robust recovery of donor immune system cells in the first two months following transplantation and eventually result in lower risk of cancer relapse, while maintaining effective graft versus host disease (GVHD) control. Patients will be randomly assigned to receive GVHD prevention therapy using one of two different immunosuppressive regimens with tacrolimus & mycophenolate mofetil (MMF). Patients assigned to the investigational group will receive MMF for 15 days following SCT with growth factor support using granulocyte macrophage colony stimulating factor (GM-CSF) beginning on post-transplant day 4. Patients randomized to the standard treatment group will receive MMF for 30 days following SCT with cytokine support using granulocyte colony stimulating factor (G-CSF) beginning on post-transplant day 4. If one of these treatment groups demonstrates an improvement in donor immune cell recovery, there may be a slow increase in the likelihood of patients being assigned to that more successful treatment group. Eventually the two groups will be compared with respect to the likelihood of either relapse or GVHD developing.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adoptive Immunotherapy in Patients With Relapsed Hematological Malignancy: Effect of Duration and Intensity of Early GVHD Prophylaxis on Long-Term Clinical Outcomes
Study Start Date : November 4, 2015
Estimated Primary Completion Date : December 31, 2025
Estimated Study Completion Date : December 31, 2025


Arm Intervention/treatment
Experimental: Arm I (MMF-15, sargramostim)
Patients receive mycophenolate mofetil PO or IV BID on days 1-15 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
Drug: mycophenolate mofetil
Given PO, by mouth, orally or IV, intravenous medication administration.
Other Name: CellCept

Biological: Sargramostim

GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.

Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.

Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF.

Other Names:
  • GM-CSF
  • colony stimulating factor 2
  • CSF2
  • granulocyte macrophage colony stimulating factor

Experimental: Arm II (MMF-30, filgrastim)
Patients receive mycophenolate mofetil PO or IV BID on days 1-30 and sargramostim SC from post-transplant day 4 until neutrophil engraftment.
Drug: mycophenolate mofetil
Given PO, by mouth, orally or IV, intravenous medication administration.
Other Name: CellCept

Biological: Filgrastim
G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
Other Names:
  • G-CSF
  • GCSF
  • colony-stimulating factor 3
  • CSF 3
  • granulocyte colony stimulating factor




Primary Outcome Measures :
  1. The differences in the relapse-free/donor lymphocyte infusion(DLI)-free survival rates between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort). [ Time Frame: 5 years ]
    The primary outcome in this study is event-free survival, where the conditional events are the occurrence of relapse or DLI.


Secondary Outcome Measures :
  1. The difference between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) day 60 donor-derived (dd) cluster of differentiation (CD)3. [ Time Frame: 5 years ]
    Day 60 donor-derived (dd) cluster of differentiation (CD)3

  2. The differences in the Overall survival (OS) between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) [ Time Frame: 5 years ]
    Overall survival (days to event or survival: time-to-event; survival: categorical)

  3. The differences in the rates of acute GVHD between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) [ Time Frame: 5 years ]
    Acute GVHD (days to positive diagnosis: time-to-event; positive diagnosis: categorical)

  4. The differences in the rates of chronic GVHD between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) [ Time Frame: 5 years ]
    Chronic GVHD (days to positive diagnosis: time-to-event; positive diagnosis: categorical)

  5. The differences in the rates of opportunistic infections between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) [ Time Frame: 5 years ]
    Rate of opportunistic infection

  6. The differences in the rates of graft loss between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) [ Time Frame: 5 years ]
    Engraftment loss (days to loss: time-to-event; graft loss: categorical)

  7. The differences in the rates of engraftment syndrome between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort) [ Time Frame: 5 years ]
    Engraftment syndrome (categorical)

  8. The differences in the rates of achieving donor chimerisms between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort). [ Time Frame: 5 years ]
    DLI administration (days to administration: time-to-event; administration: categorical)

  9. The differences in the rates of T-cell recovery kinetics following SCT between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort). [ Time Frame: 5 years ]
    Rates of T-cell recovery following SCT.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 74 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Any of the following high risk or recurrent hematological malignancies:
  • Hodgkin lymphoma (HL)
  • Non-Hodgkin lymphoma (NHL)
  • Chronic lymphocytic leukemia (CLL)
  • Multiple myeloma (MM)
  • Acute myelogenous leukemia (AML)
  • Acute lymphocytic leukemia (ALL)
  • Chronic myelogenous leukemia (CML)
  • Myelodysplastic syndrome (MDS)

    *Note: Determination that the malignancy is high risk will be made by the investigator.

  • Investigator determination that the patient is an appropriate candidate for reduced intensity allogeneic SCT with the standard Massey Cancer Center-Virginia Commonwealth Health System Bone Marrow Transplant MCC-VCUHS BMT Program regimen employed in this trial
  • Patients with or without previous myeloablative autologous transplant
  • HLA-matched stem cell donor, either related (6/6 or 5/6 loci matched) or unrelated (8/8 or 7/8 loci matched)

    *Note: Unrelated donors must be matched at HLA-A, -B, -C, and -DRB1 loci. However, a single locus mismatch will be acceptable in the event a more closely matched donor is not available.

  • Age ≥ 40 to < 75 years; patients 18 to 39 years of age will be eligible only if the investigator has determined that the patient has comorbidity(ies) precluding conventional allogeneic transplantation with full intensity myeloablative conditioning
  • Karnofsky Performance Status of 70-100%
  • Negative serology for HIV
  • Women who are not postmenopausal or have not undergone hysterectomy must have a documented negative serum pregnancy test per standard MCC-VCUHS BMT Program guidelines
  • Ability to understand and the willingness to sign a written informed consent document *Note: The consent form must be signed and dated prior to initiation of SCT preparative treatments.

Exclusion Criteria

  • Previous therapeutic radiation therapy (RT) that exceeds critical structure tolerance doses as determined by a radiation oncologist
  • Uncontrolled viral, fungal, or bacterial infection
  • Active meningeal or central nervous system disease
  • Previous therapy with rabbit anti-thymocyte globulin (ATG); previous treatment with equine ATG is allowed if more than 3 months ago

    *Note: Previous myeloablative autologous transplant is permitted but not required.

  • Pregnancy or breastfeeding
  • Medical, psychological, or social condition that, in the opinion of the investigator, may increase the patient's risk or limit the patient's adherence with study requirements

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02593123


Contacts
Contact: Catherine H Roberts, Ph.D. 804-828-1292 croberts2@vcu.edu
Contact: Amir A Toor, MD 804-628-2389 amir.toor@vcuhealth.org

Locations
United States, Virginia
Virginia Commonwealth University/Massey Cancer Center Recruiting
Richmond, Virginia, United States, 23298
Contact: Catherine Roberts, PhD    804-828-1292    croberts2@vcu.edu   
Contact: Amir A Toor, MD    804-628-2389    amir.toor@vcuhealth.org   
Principal Investigator: Amir A Toor, MD         
Sponsors and Collaborators
Virginia Commonwealth University
Massey Cancer Center
Investigators
Principal Investigator: Amir A Toor, MD Massey Cancer Center

Responsible Party: Virginia Commonwealth University
ClinicalTrials.gov Identifier: NCT02593123     History of Changes
Other Study ID Numbers: MCC-14-10739
HM20005586 ( Other Identifier: VCU Office of Research Subjects Protection )
First Posted: October 30, 2015    Key Record Dates
Last Update Posted: January 31, 2018
Last Verified: January 2018

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Virginia Commonwealth University:
Donor Type (Matched Related Donor or Matched Unrelated Donor)

Additional relevant MeSH terms:
Lymphoma
Leukemia
Multiple Myeloma
Neoplasms, Plasma Cell
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Myeloid
Hodgkin Disease
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Bone Marrow Diseases
Precancerous Conditions
Leukemia, B-Cell